Dear Dr. McConnell:

Please refer to your supplemental new drug applications submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

<table>
<thead>
<tr>
<th>Application</th>
<th>Drug Product</th>
<th>Submitted on:</th>
<th>Received on:</th>
<th>Provides for:</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA 020241/S-043</td>
<td>Lamictal (lamotrigine) tablets</td>
<td>August 5, 2010</td>
<td>August 5, 2010</td>
<td>A modified risk evaluation and mitigation strategy (REMS) and REMS Supporting Document.</td>
</tr>
<tr>
<td>NDA 020764/S-036</td>
<td>Lamictal (lamotrigine) chewable dispersible tablets</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NDA 022251/S-005</td>
<td>Lamictal ODT (lamotrigine) orally disintegrating tablets</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NDA 020241/S-044</td>
<td>Lamictal (lamotrigine) tablets</td>
<td>August 6, 2010</td>
<td>August 6, 2010</td>
<td>A Prior Approval supplement which incorporates the discussion of Aseptic Meningitis into the WARNINGS AND PRECAUTIONS section and the Medication Guide, as provided in the Agency’s July 23, 2010 e-mail request.</td>
</tr>
<tr>
<td>NDA 020764/S-037</td>
<td>Lamictal (lamotrigine) chewable dispersible tablets</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NDA 022251/S-006</td>
<td>Lamictal ODT (lamotrigine) orally disintegrating tablets</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

We also acknowledge receipt of your REMS assessment dated August 5, 2010 (submitted as part of NDA 020241/S-043, NDA 020764/S-036, and NDA 022251/S-005).
We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We request that the revised labeling approved today be available on your website within 10 days of receipt of this letter.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm), that is identical to the enclosed labeling (text for the package insert, Medication Guide) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at [http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf](http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf).

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for these NDAs, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

**RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS**

The REMS for Lamictal (lamotrigine) was approved on May 8, 2009. The REMS consists of a Medication Guide and a timetable for submission of assessments of the REMS. Your proposed modification to the REMS consists of a revised Medication Guide which includes the addition of safety information regarding the risk of aseptic meningitis.

Your proposed modified REMS, submitted on August 5, 2010 and appended to this letter, is approved. The modified REMS consists of a Medication Guide and a timetable for submission of assessments of the REMS.

The timetable for submission of assessments of the REMS will remain the same as that approved on May 8, 2009.

There are no changes to the REMS assessment plan described in our May 8, 2009 letter.

Assessments of an approved REMS must include, under section 505-1(g)(3)(B) and (C), information on the status of any postapproval study or clinical trial required under section 505(o)
or otherwise undertaken to investigate a safety issue. With respect to any such postapproval study, you must include the status of such study, including whether any difficulties completing the study have been encountered. With respect to any such postapproval clinical trial, you must include the status of such clinical trial, including whether enrollment has begun, the number of participants enrolled, the expected completion date, whether any difficulties completing the clinical trial have been encountered, and registration information with respect to requirements under subsections (i) and (j) of section 402 of the Public Health Service Act. You can satisfy these requirements in your REMS assessments by referring to relevant information included in the most recent annual report required under section 506B and 21 CFR 314.81(b)(2)(vii) and including any material or significant updates to the status information since the annual report was prepared. Failure to comply with the REMS assessments provisions in section 505-1(g) could result in enforcement action.

We remind you that in addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to the approved REMS when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of FDCA.

Prominently identify submissions containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

NDA 020241 / 020764 / 022251
REMS ASSESSMENT

NEW SUPPLEMENT FOR NDA 020241 / 020764 / 022251
PROPOSED REMS MODIFICATION
REMS ASSESSMENT

NEW SUPPLEMENT (NEW INDICATION FOR USE)
FOR NDA 020241 / 020764 / 022251
REMS ASSESSMENT
PROPOSED REMS MODIFICATION (if included)

If you do not submit electronically, please send 5 copies of REMS-related submissions.
PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to these NDAs, and to the following address:

MedWatch Program
Office of Special Health Issues
Food and Drug Administration
10903 New Hampshire Ave
Building 32, Mail Stop 5353
Silver Spring, MD 20993

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, contact Stephanie N. Keefe, Regulatory Project Manager, at (301) 796-4098.

Sincerely,

{See appended electronic signature page}

Russell Katz, M.D.
Director
Division of Neurology Products
Office of Drug Evaluation I
Center of Drug Evaluation and Research

Enclosure:
Content of Labeling
REMS
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RUSSELL G KATZ
10/24/2010